Barclays analyst Carter Gould maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report) on October 4 and set a price ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market entry ...

Opdivo carries a very high cost in the US – $12,500 a month or $150,000 for patients who stay on the drug for a year, but BMS is likely to offer the drug at a discount on this level in Europe ...

Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the time a patient lives, regardless of disease status ...

The agency has already approved Keytruda and Opdivo when combined with chemotherapy as a first-line treatment for patients with HER2-negative unresectable or metastatic gastric or gastroesophageal ...

Targeted Oncology: Please discuss the long-term data for nivolumab [Opdivo] plus ipilimumab [Yervoy] in non–small cell lung cancer (NSCLC). Ticiana Leal, MD: We now have 5-year updates from the ...

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo. A treatment combination with Yervoy (ipilimumab) plus ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

In recent years, however, doctors have turned to post-op use of immunotherapy drugs. Once such drug, Opdivo (nivolumab) received U.S. Food and Drug Administration approval in 2021 for post ...

Prior data suggested that using BMS's immune checkpoint inhibitors together — specifically, 1 milligram per kilogram of Opdivo (nivolumab) and 3 milligrams per kilogram of Yervoy (ipilimumab) — could ...